Climb Bio CLYM
NASDAQ CLYM
$10.87 +0.07 (+0.65%)
At close: Oct 21, 2026 · 4:00 PM EDT

Climb Bio (CLYM) EBITDA (2024 - 2026)

Updated

Climb Bio (CLYM) recorded EBITDA of -$15.33 million in Q2 2026, compared with -$10.64 million a year earlier.

Analysis

Climb Bio (CLYM) EBITDA (2024 - 2026) Analysis & Trends

On a TTM basis, Climb Bio's EBITDA came in at -$64.63 million as of Jun 30, 2026; for FY2025, it was -$67.79 million.

  • Across earlier years, EBITDA came in at -$82.02 million in FY2024.
  • Quarterly EBITDA has ranged from -$23.02 million in Q1 2025 to -$10.64 million in Q2 2025 over the past five years.
  • Per Business Quant, the preceding three quarters came in at -$15.17 million (Q1 2026), -$19.27 million (Q4 2025) and -$14.86 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 12.29 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 9.10 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 8.33 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 999.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 5.09 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 4.63 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -9.70 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 5.89 Bn
10 Climb Bio 823.99 Mn 343.32 Mn - -15.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.33 Mn
Mar 31, 2026 -15.17 Mn
Dec 31, 2025 -19.27 Mn
Sep 30, 2025 -14.86 Mn
Jun 30, 2025 -10.64 Mn
Mar 31, 2025 -23.02 Mn
Dec 31, 2024 -10.91 Mn
Sep 30, 2024 -11.73 Mn
API Access

Climb Bio EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=CLYM&period=max&api_key=YOUR_API_KEY